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REGULATING THE LABELING OF OVER-THE-
COUNTER DRUG PRODUCTS
Isidore Michael Schulman *
People in the United States today use over-the-counter [hereinafter
OTC] drugs far more often than prescription drugs to treat their ill-
nesses. Self-medication is relatively inexpensive and is more readily
available than professional help. In 1977 the American Pharmaceutical
Association estimated that in excess of five billion dollars worth of
OTC drug products were sold to consumers to treat over seventy per-
cent of all illnesses.I Today, the use of OTC drugs continues to grow in
importance as both the costs of medical care and the demands on phy-
sicians' time increase. This use of OTC drugs entails risks and may be
detrimental to the public's health--especially when these drugs are
misused.
By definition, consumers can use OTC drug products without con-
suiting a physician. Presumably, these drugs do not present as signifi-
cant hazards to users as do prescription drug products. However, OTC
drug products may still be dangerous. The available research in this
area indicates that the misuse of OTC drugs or misdiagnosis of medical
problems by consumers has caused serious medical complications in-
cluding chronic poisoning, physiological changes, and sometimes even
addiction.2 While this has been partly caused by the negligence or
recklessness of consumers and their inherent inability to self-diagnose
every illness, it can also be attributed to poorly designed or worded
labels.
This article explores the need for a definitive labeling program and
describes an approach which will satisfy that need. The present system
of OTC drug labeling is examined in Part I in light of the special role
the drug label plays in informing consumers of the purposes and uses
of an OTC drug product. Part II discusses the need for establishing a
uniform approach to OTC drug labeling, including adoption of a re-
quired standardized format with limited use of presently approved ter-
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Consultant to the Food and Drug Administration on Miscellaneous Internal Over-the-
Counter Drug Products (1975-1981). A.B., University of California at Berkeley. 1974: J.D.,
University of Santa Clara, 1976.
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I. THE AMERICAN PHARMACEUTICAL AssocIATION, HANDBOOK OF PRESCRIPTION DRUGs at
xi (5th ed. 1977).
2. It is difficult to trace clear figures as to the extent of these risks. However, for one good
source, see Home Medication and the Public Welfare, 136 ANN. N.Y. ACAD. SCI. 102 (1965).
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minology. Finally, in Part III, various examples of deceptive labeling
are provided along with recommendations as to how they should be
regulated under a standardized approach.
PRESENT LABELING REGULATION
A label plays a unique role in communicating information to con-
sumers. Consumers use labels to tell themselves whether the drugs suit
their needs and how the drugs are to be used. They will usually read
the label both in the store prior to purchase and in the home after
purchase. Consequently, manufacturers use drug product labels, like
advertisements, to communicate information in a style and format that
encourages product selection and, unlike advertisements, to communi-
cate precise and detailed use information. Use information facilitates
self-diagnosis. Thus, use information is particularly important when
the product is an OTC drug because an improper self-diagnosis could
cause serious harm to the consumer.
In an effort to lessen the harm caused by improper self-diagnosis,
the government could transfer all OTC drugs to prescription status.
This alternative is impractical because the price of obtaining these
products would rise, adding costs to an already expensive health-care
system. Many people who need the help of OTC drugs would go un-
treated because they could not afford to get a prescription from a doc-
tor. A better alternative, and the one our government is trying to
follow, is to remove all unsafe and ineffective products from the mar-
ketplace and to require adequate labels for those products that remain
on the OTC market. Therefore, it makes little sense for the govern-
ment to go through the long process of reviewing all OTC drug prod-
ucts for safety and effectiveness and then to allow the manufacturers to
promote approved products as they see fit. Insuring proper labeling is
a crucial element, since misuse of OTC drugs can cause as much or
more harm than ineffective or unsafe drugs.
The Food and Drug Administration [FDA] has been regulating
OTC drugs for over sixty years.3 Until 1962, its primary regulatory
approach had been to remove unsafe or misbranded OTC drug prod-
ucts from the market by means of individual court action or reclassifi-
cation of these drugs to prescription status.4 The assumption
underlying this approach was that most OTC drug products were safe
and could be marketed without FDA clearance.
After the passage of the Federal Food, Drug and Cosmetic Act
[FDCA]5 in 1962, however, the FDA approach to regulating OTC
3. Food and Drug Act of 1906, 34 Stat. 768 (1906). For a history of the earliest food and drug
laws, see Janssen, America's First Food and Drug Laws, 30 FOOD, DRUG & CosM. L.J. 665
(1975).
4. See Lee, The Enforcement Provisions of the Food, Drug, and Cosmetic Act, 6 LAW & CON-
TEMP. PROBS. 70, 70-71 (1939).
5. 21 U.S.C. §§ 301-392 (1976).
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drugs changed considerably.6 By that Act, Congress gave the FDA the
power to require a showing that all OTC drugs, prior to being mar-
keted, were safe and effective. Congress indicated to the FDA that,
among other things, the safety and effectiveness of OTC drug products
depends upon the availability of adequate and objective public infor-
mation about the products. Without such information on the label,
OTC drug products were to be considered misbranded, and the FDA
was directed to remove them from the market.7
To implement this policy the FDA initiated the OTC Drug Review
Panels [hereinafter Panels].8 These panels of experts reviewed data on
the active ingredients in OTC drug products and made recommenda-
tions to the FDA. The recommendations described the conditions
under which a drug could be considered safe, effective, and properly
labeled for OTC use.9 The recommendations were published as re-
ports, and the public has been given an opportunity to comment on
them."' The FDA has the final power of approval of the recommenda-
tions." The legality of this review process has been affirmed by the
Supreme Court 2 and reapproved by the Congress. 3 At present the
panel review process is complete but the FDA has taken final action on
only a small percentage of the reviewed drug products. 4
Although the FDA issued internal regulations which detailed the
procedures the Panels should follow, it did not provide the Panels with
much guidance as to what constitutes proper labeling.' 5 As a result of
this deficiency the labeling recommendations in the completed Panel
reports have varied widely. Consequently, as the FDA completes its
final review of the Panel reports, the lack of sufficient standards by
which to judge the adequacy of labeling has caused confusion and in-
consistent treatment of the many categories of drugs. The following
comments are an attempt to provide a framework for, and to add clar-
ity to, the FDA OTC drug labeling policy.
STANDARDIZING LABELING
Current FDA internal regulations governing OTC drug labeling do
not adequately define the criteria to be used in reviewing OTC drug
6. See Harlow, The FDA's OTC Drug Review The Development and an Analysis of Some As-
pects of the Procedure, 32 FOOD, DRUG & COSM. L.J. 248, 250 (1977).
7 21 U.S.C. §§ 352(b). 33 1(b), 334(a)(1) (1976).
8 21 C.F.R. § 330.10 (1981); 37 Fed. Reg. 85 (1972).
9. See Harlow, The FD.4s OTC Drug Review: The Development and an Analysis of Some As-
pects ofthe Procedure, 32 FOOD, DRUG & COSM. L.J. 248 (1977); 21 C.F.R. § 330.10 (1981).
10 21 C.F.R. § 330.10 (1981).
11 ld.
12. Weinberger v. Bentex Pharmaceuticals, 412 U.S. 645, 653 (1972).
13 Drug Listing Act of 1972, codified at 21 U.S.C. §§ 331, 355. 360 (1976).
14, As of January 1. 1982, only four OTC drug categories, representing two percent of all OTC
drugs to be reviewed, have been completed. 21 C.F.R. §§ 331 (antacids), 332 (antiflatulents),
310.525 (sweet spirits of nitre), 310.519 (daytime sedatives) (1981).
15. 21 C.F.R. § 201.6 (1981).
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product labels. The Panels are to consider a drug misbranded it' the
following requirement is not satisfied:
Labeling shall be clear and truthful in all respects and may not be
false or misleading in any particular. It shall state the intended uses
and results of the product; adequate directions for proper use; and
warnings against unsafe use, side effects, and adverse reactions in such
terms as to render them likely to be read and understood by the ordi-
nary individual, including individuals of low comprehension, under
customary conditions of purchase and use. 6
The lack of specificity and definition in the wording of this regula-
tion makes it more appropriate for a case-by-case review scheme than
its intended purpose as a guideline for across-the-board rulemaking.
Although some flexibility is necessary to accommodate specific cases,
the FDA should develop specific and well-defined criteria to be applied
consistently to all drug categories when determining whether the label
is adequate.
The first criterion which must be applied to any language appearing
on an OTC label is medical accuracy. The label is usually the major,
and often the only, source of information available to the consumer
about the proper use of a drug. Even when other sources are available.
consumers may rely solely on the information contained on the label
because of its convenience. Because of the reliance which consumers
place on the information appearing on an OTC drug product label. the
product cannot be considered safe and effective if that information is
inaccurate in any respect.' 7 Medical accuracy includes not only the
truthfulness of the information appearing on the label, but also the
completeness of that information. Thus, under the FDCA, the manu-
facturer is required to truthfully disclose all information necessary for
the safe and effective use of any OTC drug product."t
A standard of comprehensibility should also be applied to 01C
drug labeling language. Clear and simple language should be used in
labeling in order to maximize consumer understanding. A medically
accurate but incomprehensible label cannot promote safe and effective
self-medication.
The FDA has required that labeling information be constructed "
be read and understood by the ordinary individual, including individu-
als of low comprehension.""' This requirement cannot be met without
infusing linguistic and communicative expertise into the selection pro-
cess for every drug category. Already the Panels have made numerous
labeling recommendations that contain incomprehensible language
Although technical language may be the most medically accurate ex-
16. 21 C.F.R. § 330.10(a)(4)(v) (1981).
17. United States v. Rutherford, 442 U.S. 544 (1979).
18. 21 U.S.C. § 355(b) (1976).
19. 21 C.F.R. § 330. 10(a)(4)(v) (1981).
20. For example:
Statement of Identity and Indications-"Ophthalmic hypertonicity agent." -lot th,:
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pression of some information, when it is required it should be accom-
panied by interpretive language of common usage. Clearly, the FDA
has not perceived the importance of comprehensibility, because it con-
tinues to insist that language experts are not necessary for proper
labeling.2
Limitation of Terminology
In order to help achieve a consistent system of labeling regulation,
the FDA has developed a policy of terminology limitation. In the Ten-
tative Final Order for Antacid Products, issued on November 12, 1973,
the FDA first enunciated the policy that manufacturers may only use
specifically approved terminology for warnings, directions for use, and
indications on labels.22 This order responded to numerous comments
that "similar intent" language should be allowed. 23 The order stated
that "[t]he use of dissimilar labeling in situations involving identical
uses and hazards would cause consumer confusion and could lead to
deception and unsafe use."'24 The FDA therefore concluded that the
labeling specified in the monograph 25 would be mandatory.26
Comments submitted in response to the Tentative Final Order for
Antacid Products again requested that the FDA allow similar intent
language. In the Final Order, issued on June 4, 1974, the FDA sup-
ported its position taken in the Tentative Final Order:
The Commissioner believes that uniformity in labeling language is es-
sential to consumers. For this reason, the combining of warnings is
permitted only where it will retain uniform terminology. Allowing mi-
nor word variations, or rearrangement of the same words, would result
in dissimilar or confusing warnings which would not be in the best
interests of the public.27
Confusion over this issue persisted despite these seemingly unam-
biguous statements in the Tentative Final Order and the Final Order
for the antacid monograph. Part of the confusion arose from the lan-
guage of the Final Order, which required that "[tihe labeling of the
product represents or suggests the product as an antacid to relieve the
following symptoms: 'heartburn,' 'sour stomach,' and/or 'acid'indiges-
tion.'" (Emphasis added.)28 The FDA acknowledged the possibility of
temporary relief of corneal edema." Ophthalmic products proposed monograph, sub-
part D, § 349.70(a) and (b), 45 Fed. Reg. 30,002. 30,049 (1980).
Warnings-"Use of solution with occlusive bandages not advisable." Antimicro-
bial I products proposed monograph, subpart D, § 33.90(b)(2), 39 Fed. Reg. 33,102,
33,141 (1974).
21. 37 Fed. Reg. 9468 (1972).
22. 38 Fed. Reg. 31,260 (1973).
23. See note 10 supra and accompanying text.
24. 38 Fed. Reg. 31,260, 31,261 (1973).
25. 38 Fed. Reg. 8714 (1973).
26. 38 Fed. Reg. 31,260, 31,261 (1973).
27. 39 Fed. Reg. 19,862, 19,868 (1974).
28. Id. at 19,876.
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confusion over this language and issued an amendment which altered
the language to read: "The labeling of the product shall idenqfy the
product as an 'antacid' to alleviate the following symptoms: 'heart-
burn,' 'sour stomach,' and/or 'acid indigestion.' "(Emphasis added.)
29
The amendment notice included the Commissioner's statement that
"the terms recommended by the Panel fully meet the intent of the regu-
lation that allowing each manufacturer to select the words to be used
would result in continued consumer confusion and deception, and
therefore that the evidence presented does not justify expansion of the
present number of permitted terms."
30
Although the FDA's official policy on exclusivity has not wavered,
resistance to it continues. The drug industry maintains that this policy
is unnecessary to achieve truthful and non-deceptive OTC drug label-
ing.31 Certain Panels and Panel members have voiced support for the
industry's position. The Panel on antiperspirants went so far as to issue
a minority opinion in its proposed monograph indicating the belief of
two of its members that "to enumerate allowable words and phrases
and to disallow all others is unduly restrictive and subject to inherent
difficulty in enforcement. 32 In its proposed monograph, the Panel for
ophthalmic drug products indicated limited support for this position:
The Panel entirely supports the FDA in its determination to review,
monitor, and give approval to truthful and non-deceptive labeling to
provide consumer protection.
On the other hand, the Panel believes that industry should have the
opportunity to use unadorned synonyms to acceptable terminology as
long as it is truthful, non-deceptive, and given prior approval by
FDA.3 3
The FDA's decision to require manufacturers to use only the termi-
nology established in the monographs is dictated by the need to protect
consumers from unsafe or ineffective products. Safety and efficacy de-
terminations for OTC drug products cannot be made in the abstract.
The precise use for which the product is marketed is an integral part of
those determinations. Once the FDA has determined that a particular
product is safe and effective for a particular use, allowing the manufac-
turer to describe the product by alternative or unapproved language
could result in the marketing of the product for a use for which the
FDA had not found the product safe and effective.
By limiting the terminology with which manufacturers are allowed
to describe their OTC drug products to certain approved terms, the
FDA performs three vital services to consumers. First, restriction to
limited terminology reduces the deceptive practice of false differentia-
29. 40 Fed. Reg. 11,718, 11,719 (1974).
30. Id. at 11,718.
31. FEDERAL TRADE COMMISSION, ADVERTISING FOR OVER-THE-COUNTER DRUG ADVERTIS-
ING: STAFF REPORT 151-84 (1979) (Pub. Rec. No. 215-51).
32. 43 Fed. Reg. 46,694, 46,724-25 (1978).
33. 45 Fed. Reg. 30,002, 30,023 (1980).
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tion--use of truthful claims to mislead and falsely influence the
purchase choice of consumers.34 Second, comparison shopping for
OTC drugs is enhanced when descriptive terms are limited. Finally,
the use of limited terminology in drug labeling has an educational ef-
fect on consumers because it encourages the establishment of a stan-
dardized vocabulary of selected medical terminology. This vocabulary
assists consumers in future self-medication efforts.
The drug industry maintains that the substitution of synonyms for
approved terms will not change a truthful labeling claim into a decep-
tive one. - This argument rests on several dubious assumptions. First,
it assumes that proper synonyms of approved terminology exist. Ac-
cording to linguistic experts, the occurrence of identical or perfect syno-
nyms is extremely rare.36 Somewhat more prevalent are functional
synonyms, which are equivalents as to all important components of
meaning and in all relevant contexts.37 However, most synonyms are
of a third type. These common synonyms share some but not all im-
portant components of meaning. 38 These various types and degrees of
snyonymity suggest problems with judging the acceptability of specific
synonyns.
1he industry position is also based on the assumption that a truth-
ful claim cannot be a deceptive claim. The confusion that can result
from use of truthful claims to falsely differentiate identical products
was made apparent in the labeling of internal analgesic drugs. Internal
analgesics have been found safe and effective "for the temporary relief
of occasional minor aches, pains and headache."39 Although the Panel
reviewing analgesics also noted that internal analgesics give temporary
relief from "muscle aches," "stiffness," "pain of toothaches," "teeth-
ing," "dental procedures and dental work," "muscle soreness," "pain
due to headcolds," "nervous headache," "tension headache," and "sim-
ple pain of innoculations and immunizations,"' it decided not to allow
manufacturers to make these claims on product labels. It believed that
consumers would be confused and misled if products having identical
tormulations and offering identical therapeutic effects were marketed
for a wide variety of claimed uses.4 A consumer could mistakenly
conclude that one product is only safe and effective for "simple head-
ache." another for "tension headache" and a third for "body aches,"
and. as a result, purchase all three when any one product would be safe
and effective for the three claimed uses. It is apparent that allowing
;4. t'rohlems with this practice will be more fully discussed in Part 111 infra.
35. I:i. It:RAP_ TRADE COMMISSION, ADVERTISING FOR OVER-THE-COUNTER DRUG ADVERTIS-









manufacturers to make any-truthful claim would not always result in
truthful and non-deceptive labeling.
Another argument advanced by the drug industry in favor of un-
restricted use of unapproved truthful synonyms is that receiving FDA
approval for this terminology is either impossible or impractical.42
This argument is belied by the fact that industry participation in the
term-selection process in each of the Panels was highly encouraged.
The Panels were exhaustive in their review of labeling claims: all
claims that were submitted were reviewed. The FDA terminology limi-
tation policy gave industry an incentive to submit to the FDA all terms
that they might wish to use. To allow the use of unapproved synony-
mous terminology would have encouraged manufacturers to withhold
alternative terminology in order to avoid FDA rejection of that termi-
nology. Manufacturers desiring to use unsubmitted synonyms are not
left without recourse. Even when the word-selection process is com-
pleted and the final monograph has gone into effect, a manufacturer
may still petition the Commissioner of Food and Drugs to amend the




Use information must be communicated to consumers if it is to
serve its purpose. In addition to content, the design of the label in its
entirety and the placement of information upon it must be examined.
The FDA has been given the authority under the FDCA to regulate
OTC drug label formats;44 specifically, the conspicuousness of the in-
formation on the label.45
In accordance with the FDCA, the FDA has adopted a series of
regulations which require that information: 1) of a specific type appear
on the label,46 2) be displayed at specific places on the label," and
3) appear in a prominent manner.48
Despite these detailed regulations, the information on labels is not
as accessible as it could be. Labeling information, as currently
presented, is not necessarily salient because placement can be on the
sides or backs of labels (competing brands may differ), with lettering
42. FEDERAL TRADE COMMISSION, ADVERTISING FOR OVER-THE-COUNTER DRUGi ADVE RIis-
ING: STAFF REPORT 151-84 (1979) (Pub. Rec. No. 215-5 1).
43. 21 C.F.R. § 330.io(a)(12) (1981).
44. 21 U.S.C. § 352 (1976).
45. 21 U.S.C. § 352(c) (1976):
If any word, statement, or other information required by or under authority of this
chapter to appear on the label or labeling is not prominently placed thereon with such
conspicuousness (as compared with other words, statements, designs, or devices, in
the labeling) and in such terms as to render it likely to be read and understood by the
ordinary individual under customary conditions of purchase and use.
46. 21 C.F.R. §§ 201.1, .2, .5 (1981).
47. Id. at §§ 201.15(a)(I), .15(a)(2) (1981).
48. Id. at §§ 201.15(3)-.15(5) (1981).
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that can be difficult to read. Thus, important information may not be
likely to catch the consumer's eye in a quick scan of the label. This
may mean that much of the information that is useful before purchase
may not be read until after purchase.
Problems associated with format can be remedied by requiring bet-
ter package design. A first step would be to require standard placement
of required information. The required information could be put in the
same place on all packages, perhaps using some graphic device to make
it easily perceptible. A notice on the front of the package directing the
consumer's attention to the relevant information on the label could be
required. This reminder should be noticeable at a glance of the pack-
age. Other regulations could prohibit the use of color schemes that are
hard to read and imperceptible print styles. Word order or placement
rules could also be employed.
CONTROLLING DECEPTIVE LABELING
The FDA has broad power to regulate deceptive labeling claims.
However, the FDA has made little use of this power. Various Panels
have suggested in their final reports that the FDA, through the use of
its regulatory powers, should restrict the use of various false and mis-
leading terminology.49 The following section will consider the sugges-
tions of those Panels and delineate four types of deceptive labeling
which the FDA should actively seek to prohibit through regulation:
1) true but misleading claims, 2) false claims, 3) claims which promote
inappropriate use through truthful representations, and 4) truthful
claims which falsely differentiate between similar products.
True But Misleading Representations
Although the specifics of a given claim for a product may be true,
the general impression of that claim upon a reader may be a false one.
This may be due, in part, to the consumer's reading the label carelessly
and not noticing its subtleties. When the class of persons for whom an
OTC drug may be safe and effective is broadly defined, manufacturers
are induced to persuade persons for whom that drug would not be safe
and effective to use it.50
One form of ambiguity exists when a term used on a label is capa-
ble of varying interpretations. The Anorectal Panel discovered such an
ambiguity in the labeling of vasoconstrictor hemorrhoid products. The
Panel disallowed the use of the term "shrink" unless preceded by the
modifier "temporarily" because the use of "shrink" without such a
modifier could refer to either a temporary or a permanent condition.
The Panel concluded that the "public is likely to consider that a perma-
49. 42 Fed. Reg. 35,346, 35,434-35 (1977).




nent change is to be expected," whereas the available data indicated
that only a temporary reduction in swelling was possible.
5'
Similarly, a claim of a "guarantee of relief" is misleading unless the
conditions attached to the guarantee are provided. A vague assertion
of such a guarantee is not only unhelpful (which may or may not be
grounds for finding deception), but also may induce an otherwise unde-
sired purchase.
5 2
Labeling may also be vague or ambiguous as to an OTC drug prod-
uct's "time of onset of relief." One example of this problem is the
Cough, Cold, Allergy, Bronchodilator and Antiasthmatic Products
[CCABA] Panel's banning of the use of the words "fast" or "prompt"
because such claims were indeterminable. 53 Vague claims of this na-
ture are intended to increase product' selection rather than affect use
and therefore should be treated differently than misleading "indica-
tions for use."
One common type of misleading claim is the vague indication for
use. As the previous section discussed, the FDA presently prohibits
manufacturers from using indication-for-use claims which the FDA
has not approved. In this regard, the advisory Panels have suggested
the prohibition of indications such as "jumpy nerves," "fretfulness,"
and "under the weather. ' 54 For other potentially misleading terms
which are frequently used, a definition by the FDA would be helpful.55
This definitional approach was employed by the Topical Antimi-
crobial Panel when it chose to define rather than reject the term "anti-
septic." The Panel noted that "[olver the years, the exaggerated
labeling claims on a large variety of products containin antimicrobials
has led to misuse and abuse of the term 'antiseptic.'-56 To counteract
this effect, the Panel decided "to eliminate the confusion by developing
a rigorous definition of a Skin Antiseptic," which the Panel concluded
is "a safe, nonirritating, antimicrobial-containing preparation which
prevents overt skin infections."57 Although this approach need not re-
quire any specific action by the FDA, it should be used when possible.
To augment this system, the FDA could require that qualifying state-
ments be inserted in certain obvious cases. For example, any use of the
term "guarantee" should require further definition on the product
label.
51. 45 Fed. Reg. 35,576, 35,626 (1980).
52. See also text accompanying note 67 infra.
53. 41 Fed. Reg. 38,312, 38,343 (1976).
54. 42 Fed. Reg. 35,346, 35,355 (1977).. Other claims rejected by Panels on similar grounds in-
clude: "sustained," "prolonged," and "effective over a long period of time"-Anorectal
Panel, 45 Fed. Reg. 35,576, 35,602 (1980); "fast." "sudden," "immediate," "prompt" and
"poignant"-External Analgesic Panel, 44 Fed. Reg. 69,768, 69,844 (1979); "fast-action"-
Ophthalmic Panel, 45 Fed. Reg. 30,002, 30,035 (1980); "fast-acting," "quick," and
"prompt"-Skin Bleaching Panel, 43 Fed. Reg. 51,546, 51,554 (1978).
55. The FDA is empowered to establish such definitions by 21 U.S.C. 341 (1976).




The specific action that the FDA should take against misleading
labeling claims depends on the form of the misleading terminology.
Misleading indications for use should be absolutely prohibited. New
drug products should be approved only after their labeling claims are
approved. The FDA should also define commonly used terms like "an-
tiseptic" and ban commonly misused terms such as "shrink."
It would be difficult to require proof of claims concerning time of
onset of relief, whether that burden is placed on the manufacturer or
the FDA. Nevertheless, if a manufacturer voluntarily uses vague terms
in this manner, it should be required to show, when asked, that its
product justifies the use of such terms. Thus, a manufacturer claiming
"fast" relief would have to show (through previously submitted data)
just how its product is "fast" compared to similar products.
As to the many other possible misleading claims, the FDA should
provide manufacturers with some indication as to what is or is not ac-
ceptable. Vague, uninformative terms need not be banned, but those
which confuse or are capable of confusing the consumer into purchas-
ing an undesired product should be prohibited. In terms of advertising,
the Federal Trade Commission has taken the position that a vague
term should be interpreted broadly, thus giving the manufacturer the
benefit of the doubt.58 The FDA should have a similar rule. Finally, a
general rule against vagueness should be promulgated, although it
should be made clear that not all words which may be vague, but only
those capable of misleading a significant portion of the public, would
be prohibited.
False Representation
The plain truthfulness of language used on OTC drug labels can
usually be factually proven one way or the other. Problems for the
FDA arise, however, in drawing the line between falsity and mere
"puffing." As with misleading claims, the FDA has done very little in
this area of regulating false representations. Only now, as the Advisory
Panels complete their reports, is the FDA beginnning to face the issue
of how to regulate false representations.
It is a violation of Federal Trade Commission regulations to market
a product that is different from that being advertised, even if the con-
sumer is no worse off or even better off for having purchased it.59 Al-
though insuring the truthfulness of medical claims for OTC drug
products is a central goal of the FDA,6° it has yet to develop a policy on
truthfulness equal to the Federal Trade Commission's policy.
The most prevalent medically inaccurate claim in the OTC drug
context is the claim with no statistical support. Generally, the product
58. See. e.g., FTC v. Colgate-Palmolive Co., 380 U.S. 374 (1965).
59. FTC v. Algoma Lumber Co.. 291 U.S. 67, 78 (1934).
60. See 21 U.S.C. §§ 352(a), (f) (1976).
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will be safe and effective for some claimed use, and the label will list
that use plus others for which the product may or may not be effective.
For example, one Panel rejected claims that a bronchodilator was effec-
tive for the "relief of hayfever;" that an anticholinergic "clears nasal
passages, opens airways;" that an antihistamine "decreased nasal ob-
struction;" and that oral nasal decongestants could "overcome drowsi-
ness caused by antihistamines."'" The objection to such claims is that
there is no objective means to measure their veracity. For example,
relief of feelings of depression may be impossible to determine
objectively.
A claim may also be effectively false because it exaggerates the de-
gree of expected therapeutic benefit from an OTC drug product. One
advisory Panel rejected the term "tranquilizer" as an indication for
both nighttime and daytime sedatives. The Panel concluded that the
term "tranquilizer" is misleading because it "promises a quantitatively
different effect than that which an OTC drug is able to provide. Tran-
quilizer is a term properly identified with a medically prescribed
psychotropic drug which is available by prescription and should in fact
only be available by that source."62 The Panel chose instead to divide
the class into two groups: "daytime sedatives" and "nighttime sleep
aids." 3
Claims may be false because they have no medical meaning at all.
One Panel discovered numerous claims of this type appearing on OTC
cold product drug labels. That Panel rejected claims containing
pseudo-medical terms such as "antiallergic," and pseudo-medical ac-
tivities, such as "gets at the root of, .... fights," "wake-up," and "'multiac-
tion. '' 6 Claims which use such terms create and perpetuate confusion
and misinformation concerning proper drug use.
Claims which encourage erroneous conclusions about the causes of
certain conditions create similar misconceptions. The Antacid Panel
concluded "that claims or indications which link certain signs and
symptoms, such as 'sour breath,' 'upper abdominal pressure,' 'full feel-
ing,' 'nausea,' 'stomach distress,' 'gas,' 'indigestion,' 'upset stomach,'
and 'excessive eructations' with normal or hypernormal gastric acidity,
are unproven since the relationship of such signs and symptoms to gas-
tric acidity is unknown or dubious and there is inadequate and unrelia-
ble scientific evidence to support these claims."65 Such claims or
indications encourage the user to draw conclusions as to the cause or
intermediation of such symptoms--conclusions that even the medical
profession is incapable of drawing at this time.
Claims which explicitly or implicitly indicate treatment for condi-
61. 41 Fed. Reg. 38,312-424 (1976).
62. 40 Fed. Reg. 57,292, 57,293 (1975). Claims rejected on similar grounds include 'cathartic"
and "purgative." 40 Fed. Reg. 12,902, 12,904 (1975).
63. 40 Fed. Reg. 57,292, 57,293 (1975).
64. 41 Fed. Reg. 38,312, 38.337 (1976).
65. 38 Fed. Reg. 8714, 8722-23 (1973).
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tions for which only symptomatic relief is available are clearly medi-
cally inaccurate. One Panel determined that the "common cold" was
such a condition. The Panel found that "there is no demonstrated safe
and effective OTC active ingredient or combination of active ingredi-
ents acceptable for specific treatment of the 'common cold,' " and
therefore recommended that "product names or labeling claims that
infer or suggest a direct relationship to the 'common cold,' e.g., 'cold
medicine,' 'cold formula,' 'for relief of colds,' should not be allowed.
Such statements may mislead the consumer into believing that these
products prevent, treat, or cure the disease itself."66
Claims which "guarantee" therapeutic results are another type of
false medical claim. The Nighttime Sleep Aid Panel concluded that
" 'guaranteed' is misleading and a false promise if used in a general
way such as 'guaranteed fast-acting.' No drug helps 100 percent of the
time. The Panel believes that the word 'guarantee' should be prohib-
ited in regard to medical claims."67
Other claims which may be medically false are those that lead the
consumer to believe that the drug will induce a "natural" condition.
The Nighttime Sleep Aid Panel rejected the claims "natural sleep,"
"normal sleep" and "sound sleep" as misleading because a nighttime
sleep aid "is an exogenous non-naturally occurring agent introduced
into the body. Hence, the body is obviously not entirely in its 'natural'
state during drug-induced sleep."68 The Laxative Panel also rejected
the term "natural" in describing the therapeutic action of laxatives,
concluding that "the suggestion that a laxative is somehow 'natural'
because of its source is misleading because it implies that the product
or ingredient is a 'natural way' to induce laxation. It is not considered
'natural' to take any laxative."69
To alleviate the problems caused by false representations, the FDA
should require that all information relating to use be reviewed prior to
marketing and then ban, at that time, any terms found to be false. All
other claims which are determined to be false should be prohibited.
The FDA should establish a separate procedure to review again claims
that are discovered to be false after the product has been approved for
66. 41 Fed. Reg. 38,312. 38,377 (1976). Claims rejected on similar grounds include "'eliminates"
and "'treatment." 45 Fed. Reg. 35,576, 35, 602 (1980). Similar to claims which promise treat-
ment for an incurable condition are claims which promise treatment for a condition which
cannot exist. The Anorectal Panel, in rejecting such a claim, stated that "[blecause there are
no sensory pain-nerve fibers present in the rectal mucusa, words and phrases such as 'tempo-
rarily relieves rectal itching' and 'temporarily relieves rectal irritation' are clearly inappropri-
ate as there is no feeling of pain or itch in the rectum."
67. 40 Fed. Reg. 57,292, 57.297 (1975). False claims may also exist in situations in which a claim
is made for a particular ingredient in such a way that the consumer is led to believe that the
claim applies to the entire product. The CCABA Panel rejected such a claim made for the
safety of a nasal decongestant ingredient. The Panel stated that the "'term 'non-irritating
base' is unacceptable because it may encourage a misleading conclusion about the safety
characteristics of the total product."
68. 40 Fed. Reg. 57,292, 57,297 (1975).
69. 40 Fed. Reg. 12,902. 12,905 (1975). The Anorectal Panel rejected the claim "natural healing
is encouraged" on similar grounds. 45 Fed. Reg. 35,576, 35,602 (1980).
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market. However, the burden of proof should then shift to the FDA to
show the claim's falsity.
In addition to the above-mentioned false representations, there are
two special forms of false representation which regularly occur on OTC
drug labels--claims connected to reformulated products and claims
connected to products for which there is insufficient data to permit final
classification (Category III products). These two forms will be dis-
cussed separately below.
Drug Reformulation. As a result of the FDA's review of all OTC
drugs, many products have been identified that had little or no evi-
dence of effectiveness for their stated uses. Many of these products
have not been removed from the market. Rather, they have been refor-
mulated with ingredients which have been shown to be safe and effec-
tive. At this time the FDA does not require that reformulated products
have different trade names or that the public be notified that those
products retaining their old names have been reformulated.7"
Allowing the marketing of reformulated OTC drugs under their
original trade names without disclosing this fact on the labels can pose
an extreme hazard to consumers. This lack of information can severely
hamper treatment of common poisonings that arise from such products.
The problem may arise because either the consumer or the physician
has been misled. For example, a situation could occur where an over-
dose has been taken of a reformulated sleep-aid product that had con-
tained methapyrilene (a recently determined unsafe ingredient) prior to
reformulation. The treating physician may consult a medical reference
book that lists, under the product's name, methapyrilene as an ingredi-
ent. He would then treat for an overdose of methapyrilene, rather than
the ingredient that was actually taken. Even if he knows that the prod-
uct has been reformulated, he might not be able to determine whether
the patient took the old product with methapyrilene or the new one.
Requiring reformulated products to be renamed would let both doctor
and patient know exactly what was taken.7'
Even in situations where reformulation does not cause life-threaten-
ing hazards, it can result in consumer exposure to new or unanticipated
side effects of drug use. The advisory reports demonstrate that many
ingredients which provide equivalent therapeutic results produce very
different types of side effects. For example, the Antacid Panel found
70. The only official statement the FDA has made regarding its policy towards reformulation
was in its General Comments Section explaining its procedures for classification of OTC
drugs: "'Any drug product which is on the market and which is reformulated and/or re-
labeled within the limits of the final monograph will not lose its trademark as long as its
continued use is not misleading. Transitional labeling may be required where close ques-
tions arise." 37 Fed. Reg. 9466 (1972).
71. Similar examples where reformulation may cause confuson on the part of the physician in-
clude the reformulation of Allerest Tablets, Bromoseltzer, Cope, Liquiprin. and Nervine Ef-
fervescent Tablets (source testimony before the FTC Hearings on Over-the-Counter Drug
claims by California Citizen Action Group: Public Record 215-51).
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that among therapeutically similar ingredients, some had so few side
effects that warnings were not necessary,72 while other had toxic ef-
fects.73 While none of these side effects was likely to be life-threaten-
ing, the FDA concluded that consumers should be aware of their
existence via labeling warnings.74 However, consumers who have con-
tinued to use a particular OTC product over a period of time may not
be aware that a product has been reformulated in the absence of affirm-
ative disclosure on the label. There may be no reason for a consumer
who has read the product label once to continue to read it every time a
new purchase is made of a facially identical drug.
Furthermore, even if a consumer were to read the list of ingredients
placed on a reformulated product label, that consumer would be un-
likely to know that those ingredients are different from the old ingredi-
ents unless the difference is brought to his attention. At present,
although the new ingredients are required to be listed on the product
label,75 there is no requirement that the consumer be informed of the
change.
The lack of this requirement may also be costly to the consumer. A
company which reformulates a product and markets it under the same
trade name unfairly encourages old customers to purchase the new
product on the assumption that it is still the same as before. When the
difference becomes apparent, the customer could find out that he has
wasted his money.
One solution to this problem of potentially misinforming consumers
and physicians would be to adopt regulations prohibiting labeling re-
formulated products under the same name. This does not mean that
the previous brand name would have to be completely obliterated. It
would merely be required to be altered in such a manner as to clearly
identify the reformulated product as different from its predecessor. At
a minimum, some warning should be attached informing consumers of
the change and its possible effects.76
Category II. In 1972, under the initial procedures established to
implement the FDCA, the FDA classified each drug ingredient re-
viewed according to one of three classes: Category I ingredients are
those generally recognized as safe and effective; Category II ingredients
are those not generally recognized as safe and effective and that should
no longer be used in marketed products; and Category III are those
ingredients for which there is insufficient data to permit final classifica-
72. Eg.. aluminum. 38 Fed. Reg. 8714. 8717-18 (1973).
73. Eg., potassium, 38 Fed. Reg. 8719 (1973).
74. Id.
75. 21 C.FR. § 330.10 (1981).
76. Trademarks and trade names are clearly important in the OTC drug industry considering the
large amount of money spent by drug manufacturers in establishing brand recognition.
Therefore. if the manufacturers were to choose between changing the trade name or noticing
the reformulation, they would choose the latter.
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tion.7 7 This categorization scheme had the effect of allowing any prod-
uct with a Category III condition to remain on the market (after the
final regulations had been issued) without notification to the public.
78
This procedure was criticized by various consumer groups. In Cut-
ler v. Kennedy, a consumer group challenged the FDA's procedure of
permitting the continued marketing of certain products while testing of
their ingredients was still being conducted.79 The consumer group
charged that the FDA policy did not comply with the FDCA since that
Act does not provide for interim classifications such as Category 111.80
In July of 1979 the judge in that case (John Sirica) held in favor of the
consumer group.8' The case became binding on the FDA when it de-
cided not to appeal the decision.
In his decision, Judge Sirica held that the FDA's OTC regulations
permitting drugs with Category III conditions to be marketed after the
final regulations were issued was illegal under the provisions of the
FDCA. s2 To effectuate his decision, Judge Sirica enjoined the FDA
from implementing any portion of the disputed regulations that author-
ized the marketing of Category III drugs after final regulations were
issued.
83
The FDA has responded to the Cutler decision by proposing a pe-
riod of time after advisory Panels have completed their review, but
before any final regulations have been published, during which manu-
facturers may submit new data and information to support approval of
Category III products.8 4 In effect this response has caused no change in
FDA procedures since the Cutler lawsuit except to cause a delay in
issuing final regulations. The public is still not aware that some prod-
ucts are being allowed to be marketed that have not been approved by
the FDA.
Since there can be no official basis from which to conclude that
Category III products will perform as claimed, to permit the marketing
of these products to consumers without notification of that fact is false
or at least misleading labeling, and should be considered so by the
FDA. Because we are dealing in products which directly affect the
health and safety of the consumer, mandatory notice of this fact on
OTC drug product labels seems even more compelling. Drug manu-
facturers have been on notice since the passage of the FFCA Amend-
ments of 1962 that the safety and effectiveness of their OTC drug
products must be demonstrated to the FDA. 5
77. 21 C.F.R. §§ 330.10(a)(5)(ii) to .10(a)(5)(iii) (1981).
78. 21 C.F.R. § 330.10(a)(13) (1981).
79. Cutler v. Kennedy, 475 F. Supp. 838 (D.D.C. 1979).
80. Id. at 848.
81. Id. at 855.
82. Id.
83. Id. at 857.
84. 45 Fed. Reg. 31,422 (1980). The proposal was later adopted. 46 Fed. Reg. 47.730 (1981).
85. See note 2, supra.
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Truthful Representation Encouraging Inappropriate Use
In an effort to increase product sales a manufacturer may encourage
the use of a product for a condition for which it was not approved.
This practice is considered misbranding and is clearly unacceptable. A
manufacturer may accomplish this type of misbranding without actu-
ally claiming specific unapproved indications, but rather by using
truthful representations out of context. Such subtle misbranding is
very hard to detect. This section will elucidate several different forms
of this method of product mislabeling.
A manufacturer may produce a misleading label and justify it by
contending that it is merely using true facts in a manner favorable to it.
After all, the manufacturer argues, it is not required by the FDA to cast
information communicated on drug labels in its worst light. One way
that manufacturers distort information in this way is by not making
reference to any specific illness or condition when designating the uses
of an OTC drug product.8 6
Some consumers will then assume that the product is appropriate
for the condition they are seeking to remedy, while the product is actu-
ally not an effective or safe remedy for that condition.
Another way in which an OTC drug product label may promote
inappropriate drug use is when it contains claims for treatment of a
condition that usually requires diagnosis and care by a physician. For
example, the Anorectal Panel expressed its concern "with the use of
words or phrases describing anorectal conditions that are not easily di-
agnosed by the consumer and therefore are not appropriate for the
OTC market, such as 'anal eczema' and 'psoriasis.' "87 Furthermore,
the Panel was aware of current labeling that instructs the consumer to
use the product "before or after hemorrhoidectomy," "for anorectal
surgical wounds," "episiotomies," or "sclerosing therapy." The Panel
concluded that "such labeling is not appropriate for consumers because
these conditions are best treated under the advice and supervision of an
attending physician." 8
The Internal Analgesic Panel solved this problem in a different way
by recommending the prohibition of such claims. The Panel gave the
following reasons for its approach:
Since OTC drugs are meant to be used only for the temporary relief
of symptoms, the labeling should not indicate or imply the preparation
86. The Nighttime Sleep Aid Panel discovered such a problem. 40 Fed. Reg. 57,292, 57,318,
57,321 (1975).
87. 45 Fed. Reg. 35,576, 35,602 (1980).
88. Id. In rejecting the claim "control of minor bleeding" for vasoconstrictor drug products, the
Panel emphasized the danger of requiring consumers to distinguish between the bleeding
associated with minor abrasions and the bleeding which indicates early stages of more seri-
ous lesions such as fissures and carcinomas. The Panel noted that "[e]arly detection of carci-
noma is still the best available means of control, and this is best encouraged, in the opinion
of the Panel, by directing the user of anorectal drug products to consult the physician if
bleeding occurs for any reason." 45 Fed. Reg. 35,576, 35,626 (1980).
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is for the treatment of disease entities, such as arthritis. . . Self-medi-
cation may lead to irreversible joint damage if taken in inadequate
dosage intermittently for pain relief over prolonged periods by individ-
uals with some forms of arthritis. Since the most common forms of
arthritis, rheumatoid arthritis and osteoarthritis, are chronic diseases,
"temporary" relief by OTC analgesic doses is inappropriate therapy
for these diseases. . . . The Panel believes that any labeling for dis-
eases such as these which require medical intervention may mislead
the consumer who attempts to self-diagnose and self-treat serious dis-
eases. Therefore, the Panel strongly recommends that product names
or labeling that infer or suggest the use of these products for specific
diseases requiring prior diagnoses by a physician should not be al-
lowed. Any reference to "arthritis," "arthritis strength," "arthritis pain
formula," "rheumatism preparation," etc., in product names or label-
ing is unacceptable to the Panel. s9
Claims that downplay the risks of OTC medication should also be
of concern to the FDA. Claims of this sort can lead to casual use
which, in turn, can easily lead to misuse. Claims that promote casual
drug use create and perpetuate irresponsible self-medication by lulling
the consumer into a false sense of security in the safety and effective-
ness of OTC drugs.
For example, the Opthalmic Panel found that "[plhrasing that
promises general benefits of good health or well being or warns against
the dangers of physiological states such as 'fatigue,' 'tired eyes' or 'eyes
over forty' " are unacceptable.9 ° Along this vein, the Panel rejected
claims which indicate use for normal visual activities such as "watching
television," "reading," and "close work" or that suggest opthalmic
products "for continuous everyday use," "for improvement of tired
eyes" or "for use before putting on makeup."'" Labeling claims of this
type are particularly pernicious and should be prohibited by the FDA.
False Differentiation
Product differentiation is a commonly employed marketing tech-
nique. It is used to distinguish the product being promoted from other
like products in an attempt to direct the purchaser's selection towards
the promoted product. Mislabeling can occur if there is no sound med-
ical reason to differentiate the products.
The manufacturer may claim general product superiority or specific
superiority in comparison with other like products. These claims of
product superiority falsely differentiate products when documentation
of such superiority does not exist. For example, the Internal Analgesic
89. 42 Fed. Reg. 35,346, 35,355 (1977).
90. 45 Fed. Reg. 30,002, 30,023 (1980).
91. Id. at 30,023-24. As another example, the Laxative Panel warned against allowing language
that "promises general benefits in good health or well being." The Panel specifically banned
the term "irregularity" from laxative labeling "because 'regularity' of bowel movement is not
essential to health or well being" and therefore 'irregularity' as an indication for use is mis-
leading." 40 Fed. Reg. 12,902, 12,905, 12,912 (1975).
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Panel found general claims of product superiority, such as "special
pain relieving formula" and "enhanced relief of pain," to be "confusing
and misleading to the consumer" and therefore unacceptable.92
The CCABA Panel discovered another form of this misleading
practice. Certain manufacturers equated an increased quantity of an
active ingredient with an increased therapeutic effect. The Panel con-
cluded that there was "no justification for claiming more activity per
dose for one Category I ingredient over another because there is no
scientific merit from a therapeutic point of view between a product con-
taining 15 mg. of drug A and another containing 30 mg. of drug B if
they are similarly effective. Unsubstantiated claims for 'extra strength'
or 'contains more active ingredient per dose' or 'higher dose level' or
'stronger than' are therefore misleading. '9 3
The CCABA Panel also rejected misleading superiority claims
which "state or imply actions peculiar to a particular product, when in
fact those claims are applicable to all OTC drug products or all Cate-
gory I ingredients of the same pharmacological group."9 4 Insofar as
the claim goes to the safety and effectiveness of the product, it is verifia-
ble and should be prohibited if contrary to or not supported by infor-
mation made available to the FDA.
Claims which falsely imply that competitor's products have certain
undesirable qualities should also be found deceptive. The Anorectal
Panel rejected claims such as "contains no narcotic, anesthetic or habit-
forming ingredients," "without the use of narcotics," or "contains no
stinging, smarting, astringents" because these claims imply "that other
products are narcotics, anesthetics, or astringents and are harmful with-
out any evidence that this is so.'"' The Panel also rejected "medici-
nal," "recommended by physicians," "recommended by doctors," or
"doctor tested" as misleading "because these terms suggest that other
products are not medicine or that other products are of no value be-
cause physicians do not recommend the other products or that all phy-
sicians recommend these products."96
Claims which imply that particular therapeutic actions are peculiar
to certain products, when in fact all similar products act in the very
same way, are also misleading. For example, the CCABA Panel re-
jected the claims "travels through the bloodstream" and "works inter-
nally" because "[a]ll drugs taken internally 'work internally' and
virtually all drugs taken internally are absorbed into the bloodstream.
Thus, these claims are also not appropriate in OTC labeling." 97
Another way in which a product may be promoted truthfully and
92. 42 Fed. Reg. 35,346, 35,435 (1977).
93. 41 Fed. Reg. 38,312, 38,337 (1976).
94. Id.
95. 45 Fed. Reg. 35,376, 35,602 (1980).
96. Id.
97. 41 Fed. Reg. 38,312, 38,337 (1976).
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yet be misleading is by the use of specific indications which are merely
subparts of a larger, general condition. An example of this technique
was discovered by the Internal Analgesic Panel. The labels of certain
internal analgesic products bore claims for a variety of specific types of
pain. The Panel found that internal analgesics were equally effective
on various types of pain regardless of the source. The Panel concluded
that "the use of only a partial list of some claims such as 'low back
pains, due to over-exertion' in the labeling of one manufacturer's prod-
uct and the omission of these claims from the labeling of the same drug
by another manufacturer would mislead the user into believing the
preparations are different."98 The Panel decided to allow internal anal-
gesic products to only bear the indication: "For the temporary relief of
occasional minor aches, pains and headache."99
As was suggested for those claims encouraging inappropriate use,
claims which attempt to falsely differentiate OTC drug products by the
use of truthful representations should be prohibited. This should be
accomplished by means of regulations that can be applied equally to all
types of OTC drugs.
CONCLUSION
The FDA is in the middle of implementing a massive review of all
OTC drug products. Those products found to be unsafe, ineffective, or
misbranded are to be removed from the marketplace. However, the
positive effects of this program may never be felt by the public if the
FDA does not establish an effective uniform program to prohibit de-
ceptive and misleading labeling claims. Labeling information and for-
mat should not be allowed to vary according to the wishes of
manufacturers but should be limited to FDA approved terminology
and format. In addition, the FDA should delineate the various types of
deceptive labeling and prohibit their use. At the very least this should
include prohibiting specific forms of misleading claims, false claims,
claims which promote inappropriate use, and claims which falsely dif-
ferentiate similar products.
98. 42 Fed. Reg. 35,346, 35,435 (1977).
99. Id. at 35,422. The Panel disallowed such varied and specific indications as: "nervous tension
headache," "toothache." "pain of neuralgia," "pain of flu," "pains of minor injury," "body
aches," and "minor pain of arthritis."
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